Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Viral Factors Associated With the High Mortality Related to Human Infections With Clade 2.1 Influenza A/H5N1 Virus in Indonesia.

Pawestri HA, Eggink D, Isfandari S, Thanh TT, Rogier van Doorn H, Setiawaty V, de Jong MD.

Clin Infect Dis. 2019 Apr 26. pii: ciz328. doi: 10.1093/cid/ciz328. [Epub ahead of print]

PMID:
31321436
2.

N-Glycolylneuraminic Acid as a Receptor for Influenza A Viruses.

Broszeit F, Tzarum N, Zhu X, Nemanichvili N, Eggink D, Leenders T, Li Z, Liu L, Wolfert MA, Papanikolaou A, Martínez-Romero C, Gagarinov IA, Yu W, García-Sastre A, Wennekes T, Okamatsu M, Verheije MH, Wilson IA, Boons GJ, de Vries RP.

Cell Rep. 2019 Jun 11;27(11):3284-3294.e6. doi: 10.1016/j.celrep.2019.05.048.

3.

Genetic diversity and host adaptation of avian H5N1 influenza viruses during human infection.

Welkers MRA, Pawestri HA, Fonville JM, Sampurno OD, Pater M, Holwerda M, Han AX, Russell CA, Jeeninga RE, Setiawaty V, de Jong MD, Eggink D.

Emerg Microbes Infect. 2019;8(1):262-271. doi: 10.1080/22221751.2019.1575700.

4.

HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.

Eggink D, Bontjer I, de Taeye SW, Langedijk JPM, Berkhout B, Sanders RW.

J Biol Chem. 2019 Apr 12;294(15):5736-5746. doi: 10.1074/jbc.RA119.007360. Epub 2019 Jan 29.

5.

Fc gamma receptor IIa suppresses type I and III interferon production by human myeloid immune cells.

Newling M, Hoepel W, Vogelpoel LTC, Heineke MH, van Burgsteden JA, Taanman-Kueter EWM, Eggink D, Kuijpers TW, Beaumont T, van Egmond M, Kapsenberg ML, Baeten DLP, den Dunnen J, Jong EC.

Eur J Immunol. 2018 Nov;48(11):1796-1809. doi: 10.1002/eji.201847615. Epub 2018 Sep 14.

6.

Local amplification of highly pathogenic avian influenza H5N8 viruses in wild birds in the Netherlands, 2016 to 2017.

Poen MJ, Bestebroer TM, Vuong O, Scheuer RD, van der Jeugd HP, Kleyheeg E, Eggink D, Lexmond P, van den Brand JMA, Begeman L, van der Vliet S, Müskens GJDM, Majoor FA, Koopmans MPG, Kuiken T, Fouchier RAM.

Euro Surveill. 2018 Jan;23(4). doi: 10.2807/1560-7917.ES.2018.23.4.17-00449.

7.

HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

Eggink D, de Taeye SW, Bontjer I, Klasse PJ, Langedijk JPM, Berkhout B, Sanders RW.

J Virol. 2016 Nov 14;90(23):10587-10599. doi: 10.1128/JVI.01616-16. Print 2016 Dec 1.

8.

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW.

Cell. 2015 Dec 17;163(7):1702-15. doi: 10.1016/j.cell.2015.11.056.

9.

Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA.

J Virol. 2015 Mar;89(6):3221-35. doi: 10.1128/JVI.03337-14. Epub 2015 Jan 7.

10.

Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.

Goff PH, Eggink D, Seibert CW, Hai R, Martínez-Gil L, Krammer F, Palese P.

PLoS One. 2013 Nov 6;8(11):e79194. doi: 10.1371/journal.pone.0079194. eCollection 2013.

11.

Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.

Ortiz-Riaño E, Ngo N, Devito S, Eggink D, Munger J, Shaw ML, de la Torre JC, Martínez-Sobrido L.

J Virol. 2014 Jan;88(2):878-89. doi: 10.1128/JVI.02275-13. Epub 2013 Nov 6.

12.
13.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. doi: 10.1371/journal.pone.0067484. Print 2013.

14.

In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies.

Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P.

J Virol. 2013 Aug;87(15):8272-81. doi: 10.1128/JVI.00969-13. Epub 2013 May 22.

15.

Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs.

Seibert CW, Rahmat S, Krause JC, Eggink D, Albrecht RA, Goff PH, Krammer F, Duty JA, Bouvier NM, García-Sastre A, Palese P.

J Virol. 2013 Jul;87(14):7793-804. doi: 10.1128/JVI.00979-13. Epub 2013 May 22.

16.

Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.

de Vries RP, Smit CH, de Bruin E, Rigter A, de Vries E, Cornelissen LA, Eggink D, Chung NP, Moore JP, Sanders RW, Hokke CH, Koopmans M, Rottier PJ, de Haan CA.

J Virol. 2012 Nov;86(21):11735-44. doi: 10.1128/JVI.01084-12. Epub 2012 Aug 22.

17.

A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.

Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P.

J Virol. 2012 Jun;86(11):6179-88. doi: 10.1128/JVI.00469-12. Epub 2012 Apr 4.

18.

Is there a future for antiviral fusion inhibitors?

Berkhout B, Eggink D, Sanders RW.

Curr Opin Virol. 2012 Feb;2(1):50-9. doi: 10.1016/j.coviro.2012.01.002. Epub 2012 Jan 28. Review.

PMID:
22440966
19.

Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P.

J Virol. 2012 May;86(10):5774-81. doi: 10.1128/JVI.00137-12. Epub 2012 Mar 7.

20.

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8. doi: 10.1073/pnas.1200039109. Epub 2012 Jan 30.

21.

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW.

J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.

22.

HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

van Montfort T, Eggink D, Boot M, Tuen M, Hioe CE, Berkhout B, Sanders RW.

J Immunol. 2011 Nov 1;187(9):4676-85. doi: 10.4049/jimmunol.1101876. Epub 2011 Sep 28.

23.

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW.

J Virol. 2011 Oct;85(20):10785-97. doi: 10.1128/JVI.05331-11. Epub 2011 Aug 10.

24.

Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):206-14. doi: 10.1089/aid.2011.0101. Epub 2011 Jul 27.

25.

A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.

Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP, Sanders RW.

Retrovirology. 2011 Jun 20;8:48. doi: 10.1186/1742-4690-8-48.

26.

New pathogenic viruses and novel antiviral drugs.

Berkhout B, Eggink D.

Expert Rev Anti Infect Ther. 2011 Feb;9(2):161-3. doi: 10.1586/eri.10.166.

PMID:
21342061
27.

Inhibition of HIV-1 by fusion inhibitors.

Eggink D, Berkhout B, Sanders RW.

Curr Pharm Des. 2010;16(33):3716-28. Review.

PMID:
21128887
28.

Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW.

J Biol Chem. 2010 Nov 19;285(47):36456-70. doi: 10.1074/jbc.M110.156588. Epub 2010 Sep 8.

29.

Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW.

J Virol. 2010 Jun;84(11):5637-55. doi: 10.1128/JVI.00105-10. Epub 2010 Mar 24.

30.

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.

Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW.

Virology. 2010 Jun 5;401(2):236-47. doi: 10.1016/j.virol.2010.02.019. Epub 2010 Mar 21. Erratum in: Virology. 2010 Oct 10;406(1):162-3.

31.

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.

Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, Berkhout B, Sanders RW.

J Biol Chem. 2009 Sep 25;284(39):26941-50. doi: 10.1074/jbc.M109.004416. Epub 2009 Jul 17.

32.

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.

Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW.

J Virol. 2009 Jan;83(1):368-83. doi: 10.1128/JVI.01404-08. Epub 2008 Oct 15.

33.

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.

J Virol. 2008 Jul;82(13):6678-88. doi: 10.1128/JVI.00352-08. Epub 2008 Apr 23.

34.

The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.

Sanders RW, van Anken E, Nabatov AA, Liscaljet IM, Bontjer I, Eggink D, Melchers M, Busser E, Dankers MM, Groot F, Braakman I, Berkhout B, Paxton WA.

Retrovirology. 2008 Jan 31;5:10. doi: 10.1186/1742-4690-5-10.

35.

Antibodies to HIV-1: aiming at the right target.

Eggink D, Melchers M, Sanders RW.

Trends Microbiol. 2007 Jul;15(7):291-4. Epub 2007 Jun 12.

PMID:
17566740
36.

Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase.

Huigen MC, de Graaf L, Eggink D, Schuurman R, Müller V, Stamp A, Stammers DK, Boucher CA, Nijhuis M.

Virology. 2007 Aug 1;364(2):395-406. Epub 2007 Apr 23.

37.

Supplemental Content

Loading ...
Support Center